{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:32:08Z","timestamp":1791685928899,"version":"4.3.4"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2002,11,27]],"date-time":"2002-11-27T00:00:00Z","timestamp":1038355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biopharm &amp; Drug Disp"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pharmacokinetics of albendazole sulphoxide (ABZ\u2010SO) in three different single oral doses of albendazole (ABZ) (400, 800 and 1200 mg) was studied in 10 healthy human volunteers in a double blind three\u2010way crossover design. The serum levels of albendazole main metabolite, albendazole sulphoxide (ABZ\u2010SO), were analysed by a modified high\u2010pressure liquid chromatography method. (ABZ is not detectable in biological fluids itself.)<\/jats:p><jats:p>For ABZ\u2010SO, there was no significant difference in the biological half life, normalized serum peak concentration (<jats:italic>C<\/jats:italic><jats:sub>max\u2212ABZ\u2212SO<\/jats:sub>\/Dose<jats:sub>ABZ<\/jats:sub>), time to reach peak concentration (<jats:italic>T<\/jats:italic><jats:sub>max<\/jats:sub>) and mean residence time (MRT), whereas apparent clearance (Cl<jats:sub>p<\/jats:sub>\/<jats:italic>F<\/jats:italic>), apparent distribution volume (<jats:italic>V<\/jats:italic><jats:sub>d<\/jats:sub>\/<jats:italic>F<\/jats:italic>), normalized area under the serum concentration\u2010time curve (AUC<jats:sub>ABZ\u2212SO<\/jats:sub>\/Dose<jats:sub>ABZ<\/jats:sub>) and normalized area under the first moment curve (AUMC<jats:sub>ABZ\u2212SO<\/jats:sub>\/Dose<jats:sub>ABZ<\/jats:sub>) of albendazole main metabolite (ABZ\u2010SO) were statistically different at different doses of the parent drug, resulting in substantially lower serum concentration and thereafter AUC<jats:sub>ABZ\u2212SO<\/jats:sub>\/Dose<jats:sub>ABZ<\/jats:sub> and AUMC<jats:sub>ABZ\u2212SO<\/jats:sub>\/Dose<jats:sub>ABZ<\/jats:sub> in higher doses. These observations indicate dose dependent pharmacokinetics of albendazole (observed for ABZ\u2010SO), which were explained on the basis of a change in fraction of dose absorbed (<jats:italic>F<\/jats:italic>) as a result of slow and incomplete dissolution of the main drug in the GI tract. Copyright \u00a9 2002 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bdd.327","type":"journal-article","created":{"date-parts":[[2002,12,6]],"date-time":"2002-12-06T13:39:31Z","timestamp":1039181971000},"page":"379-383","source":"Crossref","is-referenced-by-count":23,"title":["Dose dependent pharmacokinetics of albendazole in human"],"prefix":"10.1002","volume":"23","author":[{"given":"A.","family":"Mirfazaelian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"Rouini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Dadashzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,11,27]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"869","volume-title":"Basic and Clinical Pharmacology","author":"Goldsmith RS","year":"1998"},{"key":"e_1_2_1_3_2","first-page":"1126","article-title":"Pharmacokinetics of albendazole in sheep","volume":"41","author":"Marriner SE","year":"1980","journal-title":"Am J Vet Res"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259109039463"},{"key":"e_1_2_1_5_2","first-page":"159","article-title":"Albendazole: a comparison of relay embryotoxicity with embryo\u2010toxicity of individual metabolites","volume":"12","author":"Delatour P","year":"1981","journal-title":"Ann Rech Vet"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259509061863"},{"key":"e_1_2_1_7_2","first-page":"698","article-title":"Pharmacocinetique et metabolisme urinaire de lalbendazole chez l'homme","volume":"76","author":"Penicaut B","year":"1983","journal-title":"Bull Soc Pathol Exot"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00608219"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.1984.tb00890.x"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0034-5288(18)31741-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(89)90724-4"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.38"},{"key":"e_1_2_1_13_2","first-page":"505","article-title":"Pharmacokinetic optimisation of the treatment of neurocysticercosis","volume":"43","author":"Sotelo J","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92533-3"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4269\/ajtmh.2000.63.270","article-title":"Effect of dose increase or cimetidine co\u2010administration on albendazole bioavailability","volume":"63","author":"Schipper HG","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199003000-00013"},{"key":"e_1_2_1_17_2","first-page":"563","article-title":"An HPLC method for determination of albendazole main metabolites","volume":"6","author":"Mirfazaelian A","year":"2000","journal-title":"J Pharm Pharmacol Commun"},{"key":"e_1_2_1_18_2","first-page":"607","volume-title":"Applied Biopharmaceutics and Pharmacokinetics","author":"Shargel L","year":"1999"},{"key":"e_1_2_1_19_2","first-page":"265","volume-title":"Pharmaceutical Statistics, Pharmaceutical and Clinical Applications","author":"Bolton S","year":"1997"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1992.tb03783.x"},{"key":"e_1_2_1_21_2","first-page":"893","article-title":"Neurocysticercosis","volume":"122","author":"Overbosch D","year":"1992","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00540964"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199012000-00008"},{"key":"e_1_2_1_24_2","unstructured":"WHO Food Additives Series 25 Albendazole 9\/1\/2001; 13."},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb03303.x"},{"key":"e_1_2_1_26_2","first-page":"397","article-title":"Comparative study on gastric absorption of albendazole and mebendazole in rats","volume":"100","author":"Prieto JG","year":"1991","journal-title":"Comp Biochem Physiol"}],"container-title":["Biopharmaceutics &amp; Drug Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdd.327","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdd.327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T11:44:26Z","timestamp":1700307866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdd.327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,27]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1002\/bdd.327"],"URL":"https:\/\/doi.org\/10.1002\/bdd.327","archive":["Portico"],"relation":{},"ISSN":["0142-2782","1099-081X"],"issn-type":[{"value":"0142-2782","type":"print"},{"value":"1099-081X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,27]]}}}